Dashboard
1
Poor Management Efficiency with a low ROCE of 9.89%
- The company has been able to generate a Return on Capital Employed (avg) of 9.89% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
Poor long term growth as Net Sales has grown by an annual rate of -9.90% and Operating profit at -62.81% over the last 5 years
4
Negative results in Mar 25
Stock DNA
Pharmaceuticals & Biotechnology
CNY 688 Million (Micro Cap)
41.00
NA
0.00%
-0.10
1.24%
0.51
Revenue and Profits:
Net Sales:
165 Million
(Quarterly Results - Jun 2025)
Net Profit:
7 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
15.29%
0%
15.29%
6 Months
9.01%
0%
9.01%
1 Year
23.89%
0%
23.89%
2 Years
5.08%
0%
5.08%
3 Years
-18.96%
0%
-18.96%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Zhejiang Realsun Chemical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-9.90%
EBIT Growth (5y)
-62.81%
EBIT to Interest (avg)
64.46
Debt to EBITDA (avg)
0.63
Net Debt to Equity (avg)
-0.13
Sales to Capital Employed (avg)
0.47
Tax Ratio
12.57%
Dividend Payout Ratio
75.09%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.89%
ROE (avg)
9.44%
Valuation key factors
Factor
Value
P/E Ratio
41
Industry P/E
Price to Book Value
0.51
EV to EBIT
102.62
EV to EBITDA
13.05
EV to Capital Employed
0.45
EV to Sales
0.83
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.44%
ROE (Latest)
1.24%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
165.20
175.70
-5.98%
Operating Profit (PBDIT) excl Other Income
14.10
19.90
-29.15%
Interest
0.00
0.00
Exceptional Items
-0.10
0.20
-150.00%
Consolidate Net Profit
7.00
11.60
-39.66%
Operating Profit Margin (Excl OI)
29.10%
60.20%
-3.11%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -5.98% vs -13.28% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -39.66% vs 544.44% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
628.50
658.00
-4.48%
Operating Profit (PBDIT) excl Other Income
33.70
84.70
-60.21%
Interest
0.50
0.70
-28.57%
Exceptional Items
0.00
-1.30
100.00%
Consolidate Net Profit
15.40
71.80
-78.55%
Operating Profit Margin (Excl OI)
-1.40%
83.10%
-8.45%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -4.48% vs -36.52% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -78.55% vs -62.45% in Dec 2023
About Zhejiang Realsun Chemical Co., Ltd. 
Zhejiang Realsun Chemical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






